Venus Remedies Ltd (VENUSREM) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Venus Remedies Ltd on NSE and BSE, with an AI summary of each filing.
Venus Remedies Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
Outcome · 27 Oct 2026, 12:09 am
As per the file enclosed.
Financial Result · 27 Oct 2026, 12:05 am
Outcome of Board Meeting date 26th October 2026 and Unaudited Financial Results for the period ended on 30th September 2026.
Outcome · 27 Oct 2026, 12:01 am
Venus Remedies Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Crore) ■ Revenue: 219 (+13.5% YoY | +22.3% QoQ) ■ EBITDA: 42.5 (+37.3% YoY | +24.3% QoQ) ■ EBITDA Margin (%): 19.4 (+337 bps YoY | +31 bps QoQ) ■ PAT: 25.7 (+27.4% YoY | +11.7% QoQ) ■ EPS (INR): 19.2 (+27.4% YoY | +11.7% QoQ)
As per the file enclosed.
Others (Uncategorized) · 16 Oct 2026, 8:25 pm
Venus Remedies Secures Five Marketing Authorisations Across Four Key Global Markets Venus Remedies Limited secured five marketing authorisations across Kazakhstan, Peru, Kuwait, and Argentina on 16th Oct'26, expanding its footprint across the CIS, Latin America, and Middle East regions. Key approvals include Vancomycin and Fluorouracil in Kazakhstan, Fulvestrant in Peru, Methotrexate in Kuwait, and Meropenem in Argentina. The regulatory clearances strengthen the company’s critical-care injectables and oncology export portfolio, reinforcing its global growth strategy across high-potential international markets.
As per the pdf enclosed.
Others (Uncategorized) · 14 Oct 2026, 10:51 pm
Venus Remedies Discloses Special Window for Physical Share Transfer Re-Lodgement Venus Remedies Limited informed stock exchanges on 14th Oct'26 regarding social media communications published across its official platforms (Instagram, Facebook, LinkedIn, and X). The communication provides notice to shareholders concerning the opening of a special window for the re-lodgement of transfer requests for physical shares, executed in compliance with SEBI circulars dated 2nd Jul'25 and 30th Jan'26 under Regulation 30 of SEBI LODR Regulations, 2015.
VENUS REMEDIES LIMITED has informed the Exchange about Board Meeting to be held on 26-Oct-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Quarterly ended September 2026 .
Intimation · 26 Oct 2026, 5:30 am
To consider and approve the financial results for the period ended September 30, 2026
Intimation · 26 Oct 2026, 5:30 am
Venus Remedies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/10/2026 ,inter alia, to consider and approve As per the pdf enclosed.
Intimation · 26 Oct 2026, 5:30 am
Venus Remedies Schedules Board Meeting to Approve Q2 Results Venus Remedies Limited has scheduled its Board of Directors meeting on 26th Oct'26 to consider and approve the unaudited standalone and consolidated financial results for the quarter ended 30th Sep'26. In compliance with insider trading regulations, the trading window for designated persons has been closed from 1st Oct'26 and will remain shut until 48 hours following the formal declaration of the financial results.
As per file enclosed.
Others (Uncategorized) · 01 Oct 2026, 12:12 am
Venus Remedies Updates Corporate Identification Number Following MOA Object Clause Alteration Venus Remedies Limited announced a change in its Corporate Identification Number (CIN) from L24232CH1989PLC009705 to L21002CH1989PLC009705, effective 30th Sep'26. The modification follows the alteration of the company's object clause and adoption of an amended Memorandum of Association, approved by shareholders via a Special Resolution passed on 20th Aug'26. The Ministry of Corporate Affairs has issued the Certificate of Registration confirming the registration of the altered object clause and the updated CIN.
As per the pdf enclosed.
Others (Uncategorized) · 08 Sept 2026, 6:22 pm
Venus Remedies Discloses Social Media Notices on Physical Share Transfer Window Venus Remedies Limited informed exchanges on 7th Sep'26 regarding social media communications across Facebook, Instagram, LinkedIn, and X. Under Regulation 30 of SEBI LODR Regulations, 2015, the company notified shareholders about the opening of a special window for the re-lodgement of transfer requests for physical shares, adhering to SEBI directives dated 2nd Jul'25 and 30th Jan'26.
As per file enclosed.
Annual General Meeting · 21 Aug 2026, 7:09 pm
Venus Remedies 37th AGM Voting Results and Key Resolutions Venus Remedies' 37th AGM was held on 20th Aug'26, passing all 12 resolutions. Key approvals include the adoption of FY26 financial statements and a final dividend declaration of Rs. 10 per share. Shareholders approved the re-appointment of directors Mr. Ashutosh Jain and Mr. Peeyush Jain. Several special resolutions passed, including the appointment of Mr. Saransh Chaudhary as Executive Director and Dr. (Mrs.) Manu Chaudhary's re-appointment as Joint MD. Notably, the proposal to adopt new Articles of Association received only 22.4% support from Public Institutions.
As per the file enclosed.
Others (Uncategorized) · 21 Aug 2026, 6:27 pm
Venus Remedies Updates Corporate Charter to Reflect Business Scope Venus Remedies announced shareholder approval on 20 Aug'26 for altering its Memorandum of Association (MOA) and Articles of Association (AOA). The changes align the company's object clauses with current business practices and the Companies Act, 2013. The updated MOA broadens the scope to explicitly include activities like R&D, biologics, vaccines, diagnostics, and digital health platforms. Principal business activities in the pharmaceutical sector remain unchanged. A new set of AOA compliant with the Companies Act, 2013 has also been adopted.
As per enclosed file.
Annual General Meeting · 21 Aug 2026, 6:25 pm
Venus Remedies 37th AGM Results and Key Resolutions Venus Remedies announced all 12 resolutions were passed at its 37th AGM held on 20 Aug'26. Key approvals include the declaration of a final dividend of Rs. 10 per share for FY26, the re-appointment of several directors, and the appointment of Mr. Saransh Chaudhary as Executive Director. A special resolution to adopt new Articles of Association was passed with 91.63% votes in favour, though public institutions voted 77.57% against. Another special resolution to re-appoint Dr. Savita Gupta was passed with 99.18% approval.
As per the file enclosed.
Change in Management · 20 Aug 2026, 11:05 pm
Venus Remedies Confirms Key Director Appointments and Re-appointments Venus Remedies confirmed member approval for key board changes at its AGM on 20 Aug'26. This includes the appointment of Mr. Saransh Chaudhary as Executive Director and Dr. Gurminder Singh Bedi as a Non-Executive Independent Director, both for five-year terms starting 26 May'26. Re-appointments were also approved for Dr. Manu Chaudhary as Joint Managing Director for five years from 01 Oct'26, and Dr. Savita Gupta as a Non-Executive Independent Director for a second five-year term effective 29 Dec'26, ensuring leadership continuity.
As per file enclosed.
Annual General Meeting · 20 Aug 2026, 9:41 pm
Venus Remedies AGM Approves Rs. 10/Share Dividend Venus Remedies held its 37th AGM on 20 Aug'26, approving a final dividend of Rs. 10 per equity share for FY26. Shareholders adopted the audited standalone and consolidated financial statements for the year ended 31 Mar'26. Key resolutions passed included the re-appointment of directors Mr. Ashutosh Jain and Mr. Peeyush Jain. Additionally, special resolutions were passed for the appointment of Mr. Saransh Chaudhary as Executive Director and Dr. Gurminder Singh as an Independent Director, each for a five-year term. The meeting was attended by 59 members.
Annual report for FY 2025-26.
Others (Uncategorized) · 25 Jul 2026, 12:20 am
Annual report for the FY 2025-26.
Others (Uncategorized) · 25 Jul 2026, 12:09 am
As per the pdf enclosed.
Annual General Meeting · 24 Jul 2026, 11:56 pm
As per the pdf enclosed.
Others (Uncategorized) · 21 Jul 2026, 12:16 am
Venus Remedies Approves Q1 Standalone Results & Alters MOA Venus Remedies' Board approved Q1FY27 standalone financials on 20th Jul'26. Revenue was ₹178.80 cr, down 31.0% QoQ but up 30.4% YoY. Net Profit stood at ₹25.53 cr, a 41.2% QoQ decline but a 118.2% YoY increase. The Board also approved alterations to its Memorandum of Association to align the Object Clause with current business practices. An 'Emphasis of Matter' noted a pending ₹2,859.72 Lakhs investment in its German subsidiary, Venus Pharma GmbH, which faces financial challenges amid restructuring.
As per pdf enclosed.
Financial Result · 21 Jul 2026, 12:10 am
Venus Remedies Q1FY27: PAT up 136% YoY, Approves MOA Alteration Venus Remedies reported strong Q1FY27 standalone results with PAT rising 118.2% YoY to ₹25.53 Cr. Revenue from operations grew 30.4% YoY to ₹178.80 Cr. On a QoQ basis, revenue fell 31.0% while PAT declined 41.2%. Consolidated PAT for the quarter stood at ₹22.97 Cr, up 139.3% YoY. The Board, at its meeting on 20 Jul'26, also approved alterations to the Memorandum of Association (MOA) to better align its object clause with current and proposed business activities, subject to shareholder approval.
As per the pdf enclosed.
Outcome · 21 Jul 2026, 12:04 am
Venus Remedies Ltd - Financial Result for the Quarter ended 30th Jun'26 (Consolidated, INR Crore) ■ Revenue: 179 (+30.4% YoY | -31.0% QoQ) ■ EBITDA: 34.2 (+122.3% YoY | -46.1% QoQ) ■ EBITDA Margin (%): 19.1 (+790 bps YoY | -534 bps QoQ) ■ PAT: 23.0 (+139.3% YoY | -51.6% QoQ) ■ EPS (INR): 17.2 (+139.3% YoY | -51.6% QoQ)
As per pdf enclosed.
Others (Uncategorized) · 18 Jul 2026, 10:56 pm
Venus Remedies Launches Shareholder KYC Awareness Campaign Venus Remedies Limited informed exchanges on 18 Jul'26 that it has launched a social media awareness campaign to encourage shareholders to update their Know Your Customer (KYC) details. The initiative, compliant with SEBI's Regulation 30, utilizes platforms including Facebook, Instagram, LinkedIn, and X. This action aims to enhance shareholder communication and ensure regulatory compliance by sensitizing investors to the importance of maintaining current records with the company.
Venus Remedies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/07/2026 ,inter alia, to consider and approve This is to inform you that the ....
Intimation · 20 Jul 2026, 5:30 am
Venus Remedies Board Meeting Set for 20th Jul'26 to Approve Q1 Results Venus Remedies Ltd. has scheduled a Board of Directors meeting for 20th Jul'26 to consider and approve the unaudited standalone and consolidated financial results for the quarter ending 30th Jun'26. In compliance with insider trading regulations, the trading window for designated persons has been closed from 01st Jul'26 and will reopen 48 hours after the financial results are declared. The company's stock symbols are VENUSREM on NSE and 526953 on BSE.
As per the pdf enclosed.
Others (Uncategorized) · 07 Jul 2026, 7:52 pm
Venus Remedies Announces Special Window for Physical Share Transfers Venus Remedies Limited has notified shareholders of a special window for the re-lodgement of transfer requests for physical shares. This action aligns with SEBI circulars dated 02 Jul'25 and 30 Jan'26. The company communicated this update through its official social media channels, including Facebook, Instagram, LinkedIn, and X, on 07 Jul'26. This initiative facilitates holders of physical shares to process their transfer requests, potentially improving liquidity for these shareholders and streamlining the company's registry.
As per file enclosed.
Others (Uncategorized) · 16 Jun 2026, 6:24 pm
Venus Remedies Issues Shareholder KYC Updation Advisory Venus Remedies Limited, on 16-Jun'26, informed exchanges of a social media campaign to raise shareholder awareness regarding the mandatory updation of Know Your Customer (KYC) details. The communication, disseminated across platforms like Instagram, Facebook, LinkedIn, and X, urges shareholders to update their information with the company. This action aligns with regulatory compliance under SEBI's Listing Obligations and Disclosure Requirements, 2015. No financial or operational updates were disclosed in this filing.